| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Sung Hoon Noh | Q59694457 |
| Yoon Young Choi | Q60683457 | ||
| Jae-Ho Cheong | Q63644867 | ||
| P2093 | author name string | Jae-Ho Cheong | |
| Yoon Young Choi | |||
| P2860 | cites work | Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer | Q24614511 |
| Endoscopic mucosal resection for treatment of early gastric cancer | Q24669788 | ||
| Toward Precision Medicine | Q27021937 | ||
| Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial | Q27851578 | ||
| Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer | Q27860681 | ||
| Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012 | Q27861047 | ||
| Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction | Q28215716 | ||
| Comprehensive molecular characterization of gastric adenocarcinoma | Q28244985 | ||
| Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer | Q28251814 | ||
| Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine | Q28255790 | ||
| Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer | Q28278736 | ||
| The two histological main types of gastric carcinoma: diffuse and so called intestinal-type carcinoma: an attempt at a histo-clinical classification | Q29618627 | ||
| Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer | Q29619394 | ||
| Genetic basis for clinical response to CTLA-4 blockade in melanoma | Q29620594 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study | Q29620647 | ||
| Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial | Q29620687 | ||
| Current practice of gastric cancer treatment. | Q30358173 | ||
| Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma | Q33382596 | ||
| Postoperative adjuvant 5-fluorouracil plus methyl-CCNU therapy for gastric cancer patients. Eastern Cooperative Oncology Group study (EST 3275). | Q33457798 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Minimally invasive surgery for gastric cancer treatment: current status and future perspectives | Q33633632 | ||
| Extended local resection for advanced gastric cancer: increased survival versus increased morbidity | Q34526077 | ||
| Randomized clinical trial of splenectomy versus splenic preservation in patients with proximal gastric cancer | Q34566404 | ||
| Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers | Q34620983 | ||
| Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial | Q34634440 | ||
| Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial | Q34634936 | ||
| A meta-analysis of endoscopic submucosal dissection and EMR for early gastric cancer | Q34641412 | ||
| Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up | Q34656353 | ||
| Laparoscopy-assisted Billroth I gastrectomy | Q34727889 | ||
| Gene expression signature-based prognostic risk score in gastric cancer | Q34802936 | ||
| Robotic versus Laparoscopic versus Open Gastrectomy: A Meta-Analysis. | Q35025573 | ||
| Gastric cancer screening in Korea: report on the national cancer screening program in 2008. | Q35113016 | ||
| Intrinsic subtypes of gastric cancer, based on gene expression pattern, predict survival and respond differently to chemotherapy | Q35154288 | ||
| Prediction of cancer incidence and mortality in Korea, 2015. | Q35429701 | ||
| Cancer statistics in Korea: incidence, mortality, survival, and prevalence in 2012. | Q35430015 | ||
| The future of sentinel node oriented tailored approach in patients with early gastric cancer | Q35871572 | ||
| Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer | Q36352827 | ||
| Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group | Q36619190 | ||
| Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma | Q36822182 | ||
| Changes in treatment outcomes of gastric cancer surgery over 45 years at a single institution | Q37041056 | ||
| The Japanese guidelines for gastric cancer screening | Q37111414 | ||
| The effect of spleen-preserving lymphadenectomy on surgical outcomes of locally advanced proximal gastric cancer | Q83201457 | ||
| Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial | Q84078596 | ||
| Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer | Q84365127 | ||
| Sentinel node mapping for gastric cancer: a prospective multicenter trial in Japan | Q85709668 | ||
| A phase III study of laparoscopy-assisted versus open distal gastrectomy with nodal dissection for clinical stage IA/IB gastric Cancer (JCOG0912) | Q85814194 | ||
| Morbidity and mortality after total gastrectomy for gastric malignancy using the American College of Surgeons National Surgical Quality Improvement Program database | Q88115558 | ||
| Robot-assisted gastrectomy with lymph node dissection for gastric cancer: lessons learned from an initial 100 consecutive procedures. | Q37498091 | ||
| Benefit of adjuvant chemotherapy for resectable gastric cancer: a meta-analysis | Q37742318 | ||
| Robot-assisted gastrectomy for gastric cancer: current status and technical considerations | Q38106908 | ||
| Laparoscopic gastrectomy for advanced gastric cancer: are the long-term results comparable with conventional open gastrectomy? A systematic review and meta-analysis | Q38151623 | ||
| Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. | Q38204955 | ||
| A prospective randomized study comparing open versus laparoscopy-assisted D2 radical gastrectomy in advanced gastric cancer | Q40311495 | ||
| Pancreas‐preserving total gastrectomy for proximal gastric cancer | Q40483581 | ||
| Adjuvant mitomycin and fluorouracil followed by oral uracil plus tegafur in serosa-negative gastric cancer: a randomised trial. Gastric Cancer Surgical Study Group | Q40802308 | ||
| Adjuvant chemotherapy with 5-FU, adriamycin, and mitomycin-C (FAM) versus surgery alone for patients with locally advanced gastric adenocarcinoma: A Southwest Oncology Group study | Q40963726 | ||
| Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. | Q41038524 | ||
| The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. | Q41539583 | ||
| What is the problem in clinical application of sentinel node concept to gastric cancer surgery? | Q42280532 | ||
| Morbidity and mortality of laparoscopic gastrectomy versus open gastrectomy for gastric cancer: an interim report--a phase III multicenter, prospective, randomized Trial (KLASS Trial). | Q42649289 | ||
| Major early complications following open, laparoscopic and robotic gastrectomy | Q42671093 | ||
| Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial | Q42695547 | ||
| Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer | Q43620764 | ||
| Survival benefits from splenic hilar lymph node dissection by splenectomy in gastric cancer patients: relative comparison of the benefits in subgroups of patients | Q44075052 | ||
| East meets west in the treatment of gastric cancer | Q46918207 | ||
| Advanced gastric cancer: is chemotherapy needed after surgery? | Q46975222 | ||
| Comparison of quality of life and worry of cancer recurrence between endoscopic and surgical treatment for early gastric cancer. | Q47713380 | ||
| Long-term results of laparoscopic gastrectomy for gastric cancer: a large-scale case-control and case-matched Korean multicenter study. | Q50692942 | ||
| Gastric cancer, version 2.2013: featured updates to the NCCN Guidelines. | Q50999355 | ||
| Japanese Classification of Gastric Carcinoma - 2nd English Edition - | Q51050338 | ||
| Microsatellite instability in sporadic gastric cancer: its prognostic role and guidance for 5-FU based chemotherapy after R0 resection. | Q51417165 | ||
| Rapid adaptation of robotic gastrectomy for gastric cancer by experienced laparoscopic surgeons. | Q51545148 | ||
| Japanese gastric cancer treatment guidelines 2010 (ver. 3). | Q51568719 | ||
| Gastrointestinal cancer: targeted therapies in gastric cancer-the dawn of a new era. | Q53098896 | ||
| Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. | Q53242132 | ||
| Distinctive patterns of gene expression in premalignant gastric mucosa and gastric cancer | Q59573909 | ||
| Postoperative morbidity and mortality after D1 and D2 resections for gastric cancer: preliminary results of the MRC randomised controlled surgical trial | Q60716217 | ||
| Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial | Q62628533 | ||
| A prospective, randomized evaluation of intensive-course 5-fluorouracil plus doxorubicin as surgical adjuvant chemotherapy for resected gastric cancer | Q70138560 | ||
| Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients | Q72633352 | ||
| Splenectomy in proximal gastric cancer: frequency of lymph node metastasis to the splenic hilus | Q73552680 | ||
| Impact of splenectomy for lymph node dissection on long-term surgical outcome in gastric cancer | Q74023562 | ||
| Extended lymph-node dissection for gastric cancer | Q74629358 | ||
| Randomized controlled trial to evaluate splenectomy in total gastrectomy for proximal gastric carcinoma: Japan clinical oncology group study JCOG 0110-MF | Q78477674 | ||
| Lymphadenectomy for gastric cancer | Q80204601 | ||
| Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para-aortic lymphadenectomy--Japan Clinical Oncology Group study 9501 | Q80204606 | ||
| D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer | Q81724011 | ||
| Significance of long-term follow-up of early gastric cancer | Q82584834 | ||
| Nodal dissection for patients with gastric cancer: a randomised controlled trial | Q83017438 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P433 | issue | 5 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stomach neoplasm | Q4335552 |
| precision medicine | Q17075943 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 1177-1185 | |
| P577 | publication date | 2015-09-01 | |
| P1433 | published in | Yonsei Medical Journal | Q8055114 |
| P1476 | title | Evolution of Gastric Cancer Treatment: From the Golden Age of Surgery to an Era of Precision Medicine | |
| P478 | volume | 56 |
| Q64965019 | A High Visceral-To-Subcutaneous Fat Ratio is an Independent Predictor of Surgical Site Infection after Gastrectomy. |
| Q92146535 | ADJUVANT CHEMORADIOTHERAPY AFTER SUBTOTAL OR TOTAL GASTRECTOMY AND D2 LIMPHADENECTOMY INCREASES SURVIVAL IN ADVANCED GASTRIC CANCER? |
| Q48247424 | Clinical value of peripheral blood microRNA detection in evaluation of SOX regimen as neoadjuvant chemotherapy for gastric cancer. |
| Q94606068 | Cost-Effectiveness of ramucirumab plus paclitaxel as a second-line therapy for advanced gastric or gastro-oesophageal cancer in China |
| Q37652251 | DDX5 promotes gastric cancer cell proliferation in vitro and in vivo through mTOR signaling pathway |
| Q53821747 | Distinct Expression and Prognostic Value of MS4A in Gastric Cancer. |
| Q98386388 | Distinct prognostic values and antitumor effects of tumor growth factor β1 and its receptors in gastric cancer |
| Q90446444 | Gastric Cancer in Young Adults: A Different Clinical Entity from Carcinogenesis to Prognosis |
| Q88463123 | Gastric adenocarcinoma in young adult patients: patterns of care and survival in the United States |
| Q36953980 | Genetic Variation in the TAS2R38 Bitter Taste Receptor and Gastric Cancer Risk in Koreans |
| Q88395281 | HLA-DQB1*03 genotype and perioperative blood transfusion are not conducive to the prognosis of patients with gastric cancer |
| Q55303164 | High expression of Nectin-4 is associated with unfavorable prognosis in gastric cancer. |
| Q41110505 | Immunotherapeutic Strategies for Gastric Carcinoma: A Review of Preclinical and Clinical Recent Development. |
| Q37042451 | In vitro-activated tumor-specific T lymphocytes prolong the survival of patients with advanced gastric cancer: a retrospective cohort study |
| Q59115799 | Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer |
| Q47895274 | Long-term oncological outcomes in robotic gastrectomy versus laparoscopic gastrectomy for gastric cancer: a meta-analysis. |
| Q89706755 | MicroRNA-498 inhibits the proliferation, migration and invasion of gastric cancer through targeting BMI-1 and suppressing AKT pathway |
| Q26779725 | Molecular Dimensions of Gastric Cancer: Translational and Clinical Perspectives |
| Q90164263 | Optimization of perioperative approaches for advanced and late stages of gastric cancer: clinical proposal based on literature evidence, personal experience, and ongoing trials and research |
| Q61447416 | Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial |
| Q92634633 | Socio-Demographic Disparities in Gastric Adenocarcinoma: A Population-Based Study |
| Q38867769 | Surgical Outcomes After Open, Laparoscopic, and Robotic Gastrectomy for Gastric Cancer. |
| Q64230121 | Ten Thousand Consecutive Gastrectomies for Gastric Cancer: Perspectives of a Master Surgeon |
| Q89953553 | The era of laparoscopic surgery for gastric cancer: what is the present territory and what will be next? |
| Q52651091 | The molecular mechanism of anticancer action of novel octahydropyrazino[2,1-a:5,4-a']diisoquinoline derivatives in human gastric cancer cells. |
| Q42654046 | The significance of ENAH in carcinogenesis and prognosis in gastric cancer |
| Q55040342 | miR-133a, directly targeted USP39, suppresses cell proliferation and predicts prognosis of gastric cancer. |
Search more.